Jazz, Chimerix

Jazz Pharmaceuticals bids for Chimerix in $935m deal
Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash. The deal, disclosed on Wednesday 5 March, will see Jazz pay $8.
Jazz Pharmaceuticals to buy Chimerix for $935 million
Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug candidate to treat a rare brain tumor, the companies said on Wednesday. Under the terms of the deal,
Jazz hands over $935M to buy Chimerix for near-approval cancer drug
Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO
Jazz expands in oncology with $935M deal for Chimerix
Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.
Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug
Jazz Pharmaceuticals said Wednesday it would spend nearly $1 billion to buy Chimerix and its experimental pill for a devastating brain tumor that primarily affects children and young adults.
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix
Jazz to Acquire Chimerix for $935M, Expanding Rare Oncology Portfolio
Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
Jazz Pharmaceuticals JAZZ announced that it has entered into a definitive agreement to acquire all the outstanding shares of clinical-stage biotech Chimerix CMRX for $8.55 per share in cash, aggregating to nearly $935 million.
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors--Transaction to add near-term commercial
Jazz Buys Chimerix - A Good Deal To Make With Major Approval Catalyst In Play
Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...
Why Chimerix, Inc. (CMRX) Soared Last Week
Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ ...
Chimerix deal represents ‘clear strategic fit’ for Jazz, says Stifel
Stifel reiterated a Buy rating and $230 price target on Jazz Pharmaceuticals (JAZZ) after the company agreed to acquire Chimerix (CMRX). The ...
Jazz Pharma aims to boost cancer drug pipeline with $935 million buyout
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Here are highlights from Friday’s Analyst Blog:
Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an ...
Chimerix downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to ...